ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Vivo Bio Tech has sent letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26.
Vivo Bio Tech Limited has submitted its Annual Report for the financial year 2025-2026 along with the notice for its 39th Annual General Meeting.
Vivo Bio Tech Ltd issued a notice for its 39th Annual General Meeting to be held on September 30, 2026, via video conferencing.
P.K.L Solution Private Limited, a promoter group entity, sold 6,00,000 equity shares of Vivo Bio Tech Limited. This off-market transaction reduced their stake to nil.
Vivo Bio Tech Limited announced the re-appointment of Mr. Sri Kalyan Kompella and Mr. Sankaranarayanan Alangudi as Executive Directors of the company.
Vivo Bio Tech's board meeting approved the 39th AGM date and the re-appointment of three Whole-Time Directors.
Vivo Bio Tech Limited announced that 8,10,000 promoter-allotted warrants have expired due to non-exercise within the 18-month tenure.
Vivo Bio Tech Limited announced that 483 outstanding convertible equity warrants have expired due to non-exercise within the eighteen-month tenure.
Vivo Bio Tech Ltd filed its routine quarterly shareholding pattern for the period ending June 30, 2026.
Vivo Bio Tech shareholders approved the re-appointment of Kalyan Ram Mangipudi as Whole-time Director. Related party transactions with a promoter and Virinchi Limited were also approved.
Vivo Bio Tech Ltd reported revenue from operations of ₹14.3 Cr (+14.4% YoY) and net profit of ₹0.2 Cr (-84.6% YoY) for Q1 FY27.